Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC

Phase 3IBI363Neutral

AI Analysis

Summary

Innovent Biologics announced an expansion of its Phase III MarsLight-11 trial to include non-squamous NSCLC patients, evaluating the drug IBI363 (TAK-928). This represents a routine trial protocol modification.

Clinical Trial Data

Phase

Phase III

Importance:5/10

Sentiment:

0.00

Phase_3NSCLCTrial_ExpansionInnovent_Biologics

Related Companies

$GBCYD $TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on September 28, 2026 7:11 AM

Read Original